Pharmacokinetic Herb-Drug Interactions (Part 2): Drug Interactions Involving Popular Botanical Dietary Supplements and Their Clinical Relevance (original) (raw)

Abstract

In Part 2 of this review, a critical examination of the pertinent scientific literature is undertaken in order to assess the interaction risk that popular dietary supplements may pose when taken concomitantly with conventional medications. Botanicals most likely to produce clinically important herb-drug interactions are those whose phytochemicals act as mechanism-based inhibitors of cytochrome P450 enzyme activity (e.g., Hydrastis canadensis, Piper nigrum, Schisandra chinensis) or function as ligands for orphan nuclear receptors (e.g., Hypericum perforatum). In addition, several external factors unrelated to phytochemical pharmacology can augment the drug interaction potential of botanical supplements.

Key Words

herb-drug interaction - plant secondary metabolites - cytochrome P450 enzymes - transferases - ATP-binding cassette transporters - solute carrier membrane transport proteins - botanical dietary supplements - black cohosh - Echinacea - garlic - Ginkgo biloba - ginseng - goldenseal - kava - black pepper - piperine - Schisandra - milk thistle - St. John's wort - methylenedioxyphenyl-containing compounds

References

1 Borrelli F, Izzo A A, Ernst E. Pharmacological effects of Cimicifuga racemosa. Life Sci. 2003; 73 1215-1229
2 Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause. 2003; 10 58-64
3 Shams T, Setia M S, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta analysis. Altern Health Med. 2010; 16 36-44
4 Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen?. Trend Endocrinol Metab. 2005; 16 214-221
5 Li J X, Yu Z Y. Cimicifugae rhizoma: from origins, bioactive constituents to clinical outcomes. Curr Med Chem. 2006; 13 2927-2951
6 van Breeman R B, Liang W, Banuvar S, Shulman L P, Pang Y, Tao Y, Nikolic D, Krock K M, Fabricant D S, Chen S-N, Hedayat S, Bolton J L, Pauli G F, Piersen C E, Krause E C, Geller S E, Farnsworth N R. Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh. Clin Pharmacol Ther. 2010; 87 219-225
7 Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). eCAM. 2005; 2 223-226
8 Huang Y, Jiang B, Nuntanakorn P, Kennelly E J, Shord S, Lawal T O, Soni K K, Mahady G B. Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro. Curr Drug Saf. 2010; 5 118-124
9 Jiang B, Kronenberg F, Nuntanakorn P, Qiu M-H, Kennelly E J. Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high-performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry. J Agric Food Chem. 2006; 54 3242-3253
10 Sevior D K, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O, Ahokas J T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica. 2010; 40 245-254
11 Gurley B J, Barone G W, Williams D K, Carrier J, Breen P, Yates C R, Song P, Hubbard M A, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006; 34 69-74
12 Gurley B, Hubbard M A, Williams D K, Thaden J, Tong Y, Gentry W B, Breen P, Carrier D J, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006; 46 201-213
13 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Khan I A, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005; 77 415-426
14 Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2006; 34 577-582
15 Basch E, Ulbricht C, Basch S, Dalton S, Ernst E, Foppa I, Szapary P, Tiffany N, Orlando C W, Vora M. An evidence-based systematic review of Echinacea (E. angustifolia DC, E. pallida, E. purpurea) by the Natural Standard Research Collaboration. J Herb Pharmacother. 2005; 5 57-88
16 Barnes J, Anderson L A, Gibbons S, Phillipson J D. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005; 57 929-954
17 Schoop R, Klein P, Suter A, Johnston S L. Echinacea in the prevention of induced rhinovirus colds: a meta analysis. Clin Ther. 2006; 28 174-183
18 Shah S A, Sander S, White C M, Rinaldi M, Coleman C I. Evaluation of Echinacea for the prevention and treatment of the common cold: a meta analysis. Lancet Infect Dis. 2007; 7 473-480
19 Linde K, Barrett B, Bauer R, Melchart D, Woelkart K. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006; (1) CD000530
20 Christensen L P, Brandt K. Acetylenes and psoralens. In: Crozier A, Clifford M N, Ashihara H, editors Plant secondary metabolites: occurrence, structure and role in the human diet. Oxford: Blackwell; 2006: 137-173
21 Gilroy C M, Steiner J F, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med. 2003; 163 699-704
22 Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle H P, Heilmann J. Transport of alkamides from Echinacea species through Caco-2 monolayers. Planta Med. 2002; 68 469-471
23 Matthias A, Blanchfield JT, Penman KG, Toth I, Lang C-S, De Voss JJ, Lehmann RP. Permeability studies of alkylamides and caffeic acid conjugates from Echinacea using a Caco-2 cell monolayer model. J Clin Pharm Ther. 2004; 29 7-13
24 Dietz B, Heilmann J, Bauer R. Absorption of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral application of Echinacea purpurea tincture. Planta Med. 2001; 67 863-864
25 Woelkart K, Koidl C, Grisold A, Gangemi JD, Turner RB, Marth E, Bauer R. Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans. J Clin Pharmacol. 2005; 45 683-689
26 Matthias A, Addison R S, Penman K G, Dickinson R G, Bone K M, Lehmann R P. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. Life Sci. 2005; 77 2018-2029
27 Matthias A, Gillam E M J, Penman K G, Matovic N J, Bone K M, De Voss J J, Lehmann R P. Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes. Chem Biol Interact. 2005; 155 62-70
28 Toselli F, Matthias A, Bone K M, Gillam E M J, Lehmann R P. Metabolism of the major Echinacea alkylamide _N_-isobutyldodeca-2E,4E,8Z,10Z-tetraenamide by human recombinant cytochrome P450 enzymes and human liver microsomes. Phytother Res. 2010; 24 1195-1201
29 Toselli F, Matthias A, Gillam E M J. Echinacea metabolism and drug interactions: the case for standardization of a complementary medicine. Life Sci. 2009; 85 97-106
30 Budzinski J W, Foster B C, Vandenhoek S, Arnason J T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000; 7 273-282
31 Foster B C, Vandenhoek S, Hana J, Krantis A, Akhtar M H, Bryan M, Budzinski J W, Ramputh A, Arnason J T. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine. 2003; 10 334-342
32 Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine. 2004; 11 98-104
33 Yale S H, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med. 2005; 11 433-439
34 Raner G M, Cornelious S, Moulick K, Wang Y, Mortensen A, Cech N B. Effects of herbal products and their constituents on human cytochrome P450(2E1) activity. Food Chem Toxicol. 2007; 45 2359-2365
35 Hellum B H, Nilsen O G. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol. 2007; 101 350-358
36 Budzinski J W, Trudeau V L, Drouin C E, Panahi M, Arnason J T, Foster B C. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol. 2007; 85 966-978
37 Budzinski J W, Foster B C, Trudeau V L, Drouin C E, Bafi-Yeboa N, Arnason J T. The interaction of selected phytochemicals, HIV drugs, and commercial-source herbal teas and capsules with human cytochrome P450 3A4 and P-glycoprotein. Pharm Biol. 2008; 46 53-65
38 Hellum B H, Nilsen O G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 2008; 102 466-475
39 Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol. 2007; 59 567-573
40 Hansen T S, Nilsen O G. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol. 2008; 103 445-449
41 Modarai M, Silva E, Suter A, Herinrich M, Kortenkamp A. Safety of herbal medicinal products: Echinacea and selected alkylamides do not induce CYP3A4 mRNA expression. Evid Based Complement Alternat Med. 2011; Article ID 213021, 7 pages DOI: 10.1093/ecam/nep174
42 Modarai M, Yang M, Suter A, Kortenkamp A, Heinrich M. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4). Planta Med. 2010; 76 378-385
43 Romiti N, Pellati F, Nieri P, Benvenuti S, Adinolfi B, Chieli E. P-glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal cell line. Planta Med. 2008; 74 264-266
44 Hansen T S, Nilsen O G. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. Phytother Res. 2009; 23 86-91
45 Mrozikiewicz P M, Bogacz A, Karasiewicz M, Mikolajczak P L, Ozarowski M, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozlowska T, Grzeskowiak E. The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine. 2010; 17 830-833
46 Gorski J C, Huang S M, Mitchell A P, Hamman A, Hilligoss J K, Zaheer N A, Desai M, Miller M, Hall S D. The effect of echinacea (Echinacea purpurea) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004; 75 89-100
47 Gorski J C, Jones D R, Haehner-Daniels B D, Hamman M A, O'Mara E M, Hall S D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998; 64 133-143
48 Gorski J C, Vannaprasaht S, Hamman M A, Ambrosius W T, Bruce M A, Haehner-Daniels B, Hall S D. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003; 74 275-287
49 Gurley B J, Swain A, Hubbard M A, Williams D K, Barone G, Hartsfield F, Tong Y, Carrier D J, Cheboyina S, Battu S K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res. 2008; 52 755-763
50 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Carrier J, Khan I A, Edwards D J, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004; 76 428-440
51 Penzak S R, Robertson S M, Hunt J D, Chairez C, Malati C Y, Alfaro R M, Stevenson J M, Kovacs J A. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy. 2010; 30 797-805
52 Gurley B J, Swain A, Williams D K, Barone G, Battu S K. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St John's wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008; 52 772-779
53 Freeman C, Spelman K. A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res. 2008; 52 789-798
54 Crozier A, Yokota T, Jaganath I B, Marks S C, Saltmarsh M, Clifford M N. Secondary metabolites in fruits, vegetables, beverages and other plant-based dietary components. In: Crozier A, Clifford M N, Ashihara H, editors Plant secondary metabolites: occurrence, structure and role in the human diet. Oxford: Blackwell; 2006: 208-302
55 Stevinson C, Pittler M H, Ernst E. Garlic for treating hypercholesterolemia: a meta analysis of randomized clinical trials. Ann Intern Med. 2000; 133 420-429
56 Gardner C D, Lawson L D, Block E, Chatterjee L M, Kiazand A, Balise R R, Kraemer H C. Effect of raw garlic vs. commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia. Arch Intern Med. 2007; 167 346-353
57 Pittler M H, Ernst E. Clinical effectiveness of garlic (Allium sativum). Mol Nutr Food Res. 2007; 51 1382-1385
58 Chen Z-Y, Jiao R, Ma K Y. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem. 2008; 56 8761-8773
59 Lawson L D, Wang Z J, Hughes B G. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med. 1991; 57 363-370
60 Lawson L D, Gardner C D. Composition, stability, and bioavailability of garlic products used in a clinical trial. J Agric Food Chem. 2005; 53 6254-6261
61 Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr. 2006; 136 716S-725S
62 Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J Nutr. 2001; 131 1000S-1005S
63 Simons L A, Balasubramaniam S, von Konigsmark M, Parfitt A, Simons J, Peters W. On the effect of garlic oil on plasma lipids and lipoproteins in mild hypercholesterolaemia. Atherosclerosis. 1995; 113 219-225
64 Berthold H K, Sudhop T, von Bergman K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. JAMA. 1998; 279 1900-1902
65 Smith T J, Yang C S. Effect of organosulfur compounds from garlic and cruciferous vegetables on drug metabolism enzymes. Drug Metabol Drug Interact. 2000; 17 23-49
66 Yang C S, Chhabra S K, Hong J-Y, Smith T J. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr. 2001; 131 1041S-1045S
67 Morris C R, Chen S C, Zhou L, Schopfer L M, Ding X, Mirvish S S. Inhibition by allyl sulfides and phenethyl isothiocyanate of methyl-n-pentylnitrosamine depentylation by rat esophageal microsomes, human, and rat CYP2E1, and rat CYP2A3. Nutr Cancer. 2004; 48 54-63
68 Wargovich M J. Diallylsulfide and allylmethylsulfide are uniquely effective among organosulfur compounds in inhibiting CYP2E1 protein in animal models. J Nutr. 2006; 136 832S-834S
69 Black G P, Collins K S, Blacquiere D P, Forkert P-G. Formation of N-alkylprotoporphyrin IX from metabolism of diallyl sulfone in lung and liver. Drug Metab Dispos. 2006; 34 895-900
70 Haber D, Siess M H, Canivenc-Lavier M C, Le Bon A M, Suschetet M. Differential effects of dietary diallyl sulfide and diallyl disulfide on rat intestinal and hepatic drug-metabolizing enzymes. J Toxicol Environ Health. 1995; 44 423-434
71 Siess M, Le Bon A M, Canivenc-Lavier M C, Suschetet M. Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett. 1997; 120 195-201
72 Wu C C, Sheen L Y, Chen H-W, Kuo W W, Tsai S J, Lii C-K. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem. 2002; 50 378-383
73 Tsai C-W, Yang J-J, Chen H-W, Sheen L-Y, Lii C-K. Garlic organosulfur compounds upregulate the expression of the pi class of glutathione S-transferase in rat primary hepatocytes. J Nutr. 2005; 135 2560-2565
74 Zhang P, Noordine M-L, Cherbuy C, Vaugelade P, Pascussi J M, Duée P-H, Thomas M. Different activation patterns of rat xenobiotic metabolism genes by two constituents of garlic. Carcinogenesis. 2006; 27 2090-2095
75 Krizkova J, Burdova K, Hudecek J, Stiborova M, Hodek P. Induction of cytochromes P450 in small intestine by chemopreventative compounds. Neuro Endocrinol Lett. 2008; 29 717-721
76 Lubet R A, Yao R, Grubbs C J, You M, Wang Y. Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element. Chem Biol Interact. 2009; 182 22-28
77 Fisher C D, Augustine L M, Maher J M, Nelson D M, Slitt A L, Klaassen C D, Lehman-McKeeman L D, Cherrington N J. Induction of drug metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos. 2007; 35 995-1000
78 Engdal S, Nilsen O G. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res. 2009; 23 906-912
79 Zou L, Harkey M R, Henderson G L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002; 71 1579-1589
80 Foster B C, Foster M S, Vandenhoek S, Krantis A, Budzinski J W, Arnason J T, Gallicano K D, Choudri S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci. 2001; 4 176-184
81 Greenblatt D J, Leigh-Pemberton R A, von Moltke L L. In vitro interactions of water-soluble garlic components with human cytochromes P450. J Nutr. 2006; 136 806S-809S
82 Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventative phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun. 2005; 327 866-870
83 Engdal S, Nilsen O G. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica. 2008; 38 559-573
84 Arora A, Seth K, Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis. 2004; 25 941-949
85 Demeule M, Brossard M, Turcotte S, Regina A, Jodoin J, Béliveau R. Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression. Biochem Biophys Res Commun. 2004; 324 937-945
86 Berginc K, Zakelj S, Ursic D, Kristl A. Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull. 2009; 32 694-699
87 Berginc K, Zakelj S, Kristl A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetes patients. Eur J Nutr. 2010; 49 373-384
88 Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet. 2010; 25 307-313
89 Payen L, Sparfel L, Courtois A, Vernhet L, Guillouzo A, Fardel O. The drug efflux pump MRP-2: regulation of expression in physiopathological situations by endogenous and exogenous compounds. Cell Biol Toxicol. 2002; 18 221-233
90 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Cui Y, Ang C Y W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002; 72 276-287
91 Gwilt P R, Lear C L, Tempero M A, Birt D D, Grandjean A C, Ruddon R W, Nagel D L. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev. 1994; 3 155-160
92 Loizou G D, Crocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol. 2001; 20 321-327
93 Piscitelli S C, Burstein A H, Welden N, Gallicano K D, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002; 34 234-238
94 Gallicano K, Foster B, Choudri S. Effect of short-term administration of garlic supplements on single-dose pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2003; 55 199-202
95 Markowitz J S, DeVane L, Chavin K D, Taylor R M, Ruan Y, Donovan J L. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther. 2003; 74 170-177
96 Jacek H, Rentsch K M, Steinert H C, Pauli-Magnus C, Meier P J, Fattinger K. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test [Abstr]. Clin Pharmacol Ther. 2004; 75 80
97 Jabbari A, Argani H, Ghorbanihaghjo A, Mahdavi R. Comparison between swallowing and chewing of garlic on levels of serum lipids, cyclosporine, creatinine and lipid peroxidation in renal transplant recipients. Lipids Health Dis. 2005; 4 11
98 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Cui Y, Ang C Y W. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005; 22 525-539
99 Cox M C, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter M G, Petros W P, Proce D K, Figg W D, Sparreboom A, Swain S M. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res. 2006; 12 4636-4640
100 Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006; 136 793S-795S
101 Abdul M I M, Jiang X, Willaims K M, Day R O, Roufogalis B D, Liauw W S, Ku H, McLachlan A J. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008; 154 1691-1700
102 Yang L-J, Fan L, Liu Z-Q, Mao Y-M, Guo D, Liu L-H, Tan Z-R, Peng L, Han C-T, Hu D-L, Wang D, Zhou H-H. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Eur J Clin Pharmacol. 2009; 65 601-608
103 Hajda J, Rentsch K M, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci. 2010; 41 729-735
104 Chan P-C, Xia Q, Fu P P. Ginkgo biloba leaves extract: biological, medicinal, and toxicological effects. J Environ Sci Health C. 2007; 25 211-244
105 Zhou W, Chai H, Lin P H, Lumsden A B, Yao Q, Chen C. Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. Cardiovasc Drug Rev. 2004; 22 309-319
106 Canter P H, Ernst E. Ginkgo biloba is not a smart drug: an updated systematic review of randomized clinical trials testing the nootropic effects of G. biloba extracts in healthy people. Hum Psychopharmacol. 2007; 22 265-278
107 Ramassamy C, Longpré F, Christen Y. Ginkgo blioba extract (EGb 761) in Alzheimer's disease: is there any evidence?. Curr Alzheimer Res. 2007; 4 253-262
108 Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009; (1) CD003120
109 Nicolaï S P, Kruidenier L M, Bendermacher B L, Prins M H, Teijink J A. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2009; (2) CD006888
110 Kressman S, Müller W E, Blume H H. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol. 2002; 54 661-669
111 Woelkert K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res. 2010; 24 445-450
112 Etheridge A S, Black S R, Patel P R, So J, Mathews J M. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007; 73 731-741
113 Hellum B H, Hu Z, Nilsen O G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2007; 100 23-30
114 Hellum B H, Hu Z, Nilsen O G. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol. 2009; 105 58-63
115 Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun. 2004; 318 1072-1078
116 Chang T K H, Chen J, Yeung E Y H. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol. 2006; 213 18-26
117 Numa A M, Abbott F S, Chang T K H. Effect of Ginkgo biloba extract on oxidative metaolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. Can J Physiol Pharmacol. 2007; 85 848-855
118 Lau A J, Chang T K H. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos. 2009; 37 1931-1937
119 Mohamed M F, Frye R F. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos. 2010; 38 270-275
120 He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther. 2004; 11 206-212
121 Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol. 2010; 48 429-435
122 Tiong K H, Yiap B C, Tan E L, Ismail R, Ong C E. In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity. Xenobiotica. 2010; 40 458-466
123 Kuo I F, Chen J, Chang T K H. Effect of Ginkgo biloba extract on rat hepatic microsomal CYP1A activity: role of ginkgolides, bilobalide, and flavonols. Can J Physiol Pharmacol. 2004; 82 57-64
124 von Moltke L L, Weemhoff J L, Bedir E, Khan I A, Harmatz J S, Goldman P, Greenblatt D J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol. 2004; 56 1039-1044
125 Hodek P, Trefil P, Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact. 2002; 139 1-21
126 Si D, Wang Y, Zhou Y-H, Guo Y, Wang J, Zhou H, Li Z-S, Fawcett J P. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos. 2009; 37 629-634
127 He N, Xie H-G, Collins X, Edeki T, Yan Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol. 2006; 33 813-815
128 Chang T K H, Chen J, Teng X W. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab Dispos. 2006; 34 234-242
129 Yeung E Y H, Sueyoshi T, Negishi M, Chang T H K. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos. 2008; 36 2270-2276
130 Deng Y, Bi H C, Zhao L Z, Wang X D, Chen J, Ou Z M, Ding L, Xu L J, Guan S, Chen X, Zhou S F, Huang M. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett. 2008; 2 60-66
131 Li L, Stanton J D, Tolson A H, Luo Y, Wang H. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009; 26 872-882
132 Rajaraman G, Yang G, Chen J, Chang T H K. Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can J Physiol Pharmacol. 2009; 87 674-683
133 Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem. 2008; 56 5366-5373
134 Jeuken A, Keser B J G, Khan E, Brouwer A, Koeman J, Denison M S. Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J Agric Food Chem. 2003; 51 5478-5487
135 Sasaki K, Hatta S, Wada K, Ueda N, Yoshimura T, Endo T, Sakata M, Tanaka T, Haga M. Effects of extract of Ginkgo biloba leaves and its constituents on carcinogen-metabolizing enzyme activities and glutathione levels in mouse liver. Life Sci. 2002; 70 1657-1667
136 Umegaki K, Saito K, Kubota Y, Sanada H, Yamada K, Shinozuka K. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn J Pharmacol. 2002; 90 345-351
137 Yang X F, Wang N P, Lu W H, Zeng F D. Effects of Ginkgo biloba extract and tanshinone on cytochrome P-450 isozymes and glutathione transferase in rats. Acta Pharmacol Sin. 2003; 24 1033-1038
138 Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Yamada K, Umegaki K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem Toxicol. 2004; 42 953-957
139 Chatterjee S S, Doelman C J, Nöldner M, Biber A, Koch E. Influence of the Ginkgo extract EGb 761 on rat liver cytochrome P450 and steroid metabolism and excretion in rats and man. J Pharm Pharmacol. 2005; 57 641-650
140 Guo L, Mei N, Liao W, Chan P-C, Fu P P. Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network. Omics. 2010; 14 75-89
141 Shinozuka K, Umekagi K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J, Nakamura K, Kunitomo M. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci. 2002; 70 2783-2792
142 Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Wu J, Umegaki K. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci. 2004; 75 1113-1122
143 Kubota Y, Kobayashi K, Tanaka N, Nakamura K, Kunimoto M, Umegaki K, Shinozuka K. Pretreatment with Ginkgo biloba extract weakens the hypnosis action of phenobarbital and its plasma concentration in rats. J Pharm Pharmacol. 2004; 56 401-405
144 Zhao L-Z, Huang M, Chen J, Ee P L R, Chan E, Duan W, Guan Y-Y, Hong Y-H, Chen X, Zhou S. Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr Drug Metab. 2006; 7 577-587
145 Yang C Y, Chao P D L, Hou Y C, Tsai S Y, Wen K C, Hsiu S L. Marked decrease of cyclosporine bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol. 2006; 44 1572-1578
146 Tang J, Sun J, Zhang Y, Li L, Cui F, He Z. Herb-drug interactions: effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem Toxicol. 2007; 45 2441-2445
147 Rajaraman G, Chen J, Chang T K H. Ginkgolide A contributes to the potentiation of acetaminophen toxicity by Ginkgo biloba extract in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol. 2006; 217 225-233
148 Umegaki K, Taki Y, Endoh K, Taku K, Tanabe H, Shinozuka K, Sugiyama T. Bilobalide in Ginkgo biloba extract is a major substance inducing hepatic CYPs. J Pharm Pharmacol. 2007; 59 871-877
149 Deng Y, Bi H-C, Zhao L-Z, He F, Liu Y-Q, Yu J-J, Ou Z-M, Ding L, Huang Z-Y, Huang M, Zhou S-F. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica. 2008; 38 465-481
150 Taki Y, Yamazaki Y, Shimura F, Yamada S, Umegaki K. Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci. 2009; 109 459-462
151 Yin O Q P, Tomlinson B, Waye M M Y, Chow A H L, Chow M S S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004; 14 841-850
152 Duche J C, Barre J, Guinot P, Duchier J, Cournot A, Tillement J P. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharm Res. 1989; 9 165-168
153 Smith M, Lin K M, Zheng Y P. An open trial of nifedipine-herb interactions: nifedipine with St John's wort, ginseng, or Ginkgo biloba [Abstr.]. Clin Pharmacol Ther. 2001; 69 P86
154 Sun H, Zuo Z, Yin O Q, Tomlinson B, Chow M S. A high-throughput cocktail method for screening the effect of herbal product on liver isozyme activities: experience with Ginkgo biloba. Clin Pharmacol Ther. 2002; 71 P100
155 Engelsen J, Nielsen J D, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomized, double blind, placebo-crossover trial. Thromb Haemost. 2002; 87 1075-1076
156 Mauro V F, Mauro L S, Kleshinski J F, Khuder S A, Wang Y, Erhardt P W. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther. 2003; 10 247-251
157 Markowitz J S, Donovan J L, DeVane L, Sipkes L, Chavin K D. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol. 2003; 23 576-581
158 Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull. 2004; 27 2006-2009
159 Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol. 2004; 44 538-542
160 Jiang X, Williams K M, Liauw W S, Ammit A J, Roufogalis B D, Duke C C, Day R O, McLachlan A J. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005; 59 425-432
161 Markowitz J S, DeVane C L, Lewis J G, Chavin K D, Wang J-S, Donovan J L. Effect of Ginkgo biloba extract on plasma steroid concentrations in healthy volunteers: a pilot study. Pharmacotherapy. 2005; 25 1337-1340
162 Aruna D, Naidu M U R. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol. 2006; 63 333-338
163 Mohutsky M A, Anderson G D, Miller J W, Elmer G W. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther. 2006; 13 24-31
164 Greenblatt D J, von Moltke L L, Luo Y, Perloff E S, Horan K A, Bruce A, Reynolds R C, Harmatz J S, Avula B, Khan I A, Goldman P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol. 2006; 46 214-221
165 Lu W-J, Huang J, Lai M-L. The effects of ergoloid mesylates and Ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006; 46 628-634
166 Uchida S, Yamada H, Li X D, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol. 2006; 46 1290-1298
167 Wolf H R D. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?. Drugs R D. 2006; 7 163-172
168 Jiang X, Blair E Y L, McLachlan A J. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol. 2006; 46 1370-1378
169 Kudolo G B, Wang W, Javors M, Blodgett J. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects – A double blind placebo-controlled, crossover study. Clin Nutr. 2006; 25 606-616
170 Robertson S M, Davey R T, Voell J, Formentini E, Alfaro R M, Penzak S R. Effect of Ginkgo biloba extract on lopinavir, midazolam, and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin. 2008; 24 591-599
171 Lei H P, Wang G, Wang L S, Ou-yang D, Chen H, Zhang W, Tan Z-R, Fan L, He Y-J, Zhou H-H. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009; 43 726-731
172 Fan L, Mao X-Q, Tao G Y, Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei H-P, Hu D L, Huang Y-F, Wang D, Zhou H-H. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica. 2009; 39 249-254
173 Fan L, Tao G-Y, Wang G, Chen Y, Zhang W, He Y-J, Li Q, Lei H-P, Jiang F, Hu D-L, Huang Y-F, Zhou H-H. Effects of Ginkgo biloba extract ingestion on the pharmcokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother. 2009; 43 944-949
174 Lei H-P, Ji W, Lin J, Chen H, Tan Z-R, Hu D-L, Liu L-J, Zhou H-H. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol. 2009; 68 201-206
175 Zuo X-C, Zhang B-K, Jia S-J, Liu S-K, Zhou L-Y, Li J, Zhang J, Dai L-L, Chen B-M, Yang G-P, Yuan H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010; 66 503-509
176 Kim B-H, Kim K-P, Lim K S, Kim J-R, Yoon S H, Cho J-Y, Lee Y-O, Lee K-H, Jang I-J, Shin S-G, Yu K-S. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther. 2010; 32 380-390
177 Food and Drug Administration .Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling. Available at: http://www.fda.gov/Drugs/Guidance%20Compliance%20Regulatory%20Information/Guidances/ucm064982.htm Accessed 2010 Jul 17
178 Huang S M, Temple R, Throckmorton D C, Lesko L J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007; 81 298-304
179 Lau A J, Yang G, Rajaraman, Baucom C C, Chang T K H. Species-dependent and receptor-selective action of bilobalide on the function of constitutive androstane receptor and preganane X receptor. Drug Metab Dispos. 2012; 40 178-186
180 Mauri P, Simonetti P, Gardana C, Minoggio M, Morazzoni P, Bombardelli E, Pietta P. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun Mass Spectrom. 2001; 15 929-934
181 Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry. 2003; 36 S32-S37
182 Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res. 2010; 24 445-450
183 Kressmann S, Müller W E, Blume H H. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol. 2002; 54 661-669
184 Kressmann S, Biber A, Wonnemann M, Schug B, Blume H H, Müller W E. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol. 2002; 54 1507-1514
185 Madgula V L, Avula B, Yu Y B, Tchantchou F, Fisher S, Luo Y, Khan I A, Khan S I. Intestinal and blood-brain barrier permeability of ginkgolides and bilobalide: in vitro and in vivo approaches. Planta Med. 2010; 76 599-606
186 Jia L, Zhao Y, Liang X-J. Current evaluation of the millennium phytomedicine – ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem. 2009; 16 2924-2942
187 Vogler B K, Pittler M H, Ernst E. The efficacy of ginseng. A systematic review of randomized clinical trials. Eur J Clin Pharmacol. 1999; 55 567-575
188 Buettner C, Yeh G Y, Phillips R S, Mittleman M A, Kaptchuk T J. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother. 2005; 39 83-95
189 Luo J Z, Luo L. Ginseng on hyperglycemia: effects and mechanisms. eCAM. 2009; 6 423-427
190 Christensen L P. Ginsenosides: chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res. 2008; 55 1-99
191 Chen C, Choiu W, Zhang J. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. Acta Pharmacol Sin. 2008; 29 1103-1108
192 Tawab M A, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides on humans after oral administration. Drug Metab Dispos. 2003; 31 1065-1071
193 Bae E-A, Han M J, Kim E-J, Kim D-H. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res. 2004; 27 61-67
194 Lee J, Lee E, Kim D, Lee J, Yoo J, Koh B. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. J Ethnopharmacol. 2009; 122 143-148
195 Ling Y, Yong L, Chang-Xiao L. Metabolism and pharmacokinetics of ginsenosides. Asian J Pharmacodynam Pharmacokinet. 2006; 6 103-120
196 Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside; deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004; 95 153-157
197 Han M, Fang X. Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models. Acta Pharmacol Sin. 2006; 27 499-505
198 Xie H-T, Wang G-J, Chen M, Jiang X, Li H, Lv H, Huang C-R, Wang R, Roberts M. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol Pharm Bull. 2005; 28 383-386
199 Gu Y, Wang G-J, Wu X-L, Zheng Y-T, Zhang J-W, Ai H, Sun J-G, Jia Y-W. Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters. Xenobiotica. 2010; 40 602-612
200 Henderson G L, Harkey M R, Gershwin M E, Hackman R M, Stern J S, Stresser D M. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Pharmacol Lett. 1999; 65 209-214
201 Chang T K H, Chen J, Benetton S A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos. 2002; 30 378-384
202 Kim S-W, Kwon H, Chi D-W, Shim J-H, Park J-D, Lee Y-H, Pyo S, Rhee D-K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem Pharmacol. 2003; 65 75-82
203 Liu Y, Zhang J-W, Li W, Ma H, Sun J, Deng M-C, Yang L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006; 91 356-364
204 Liu Y, Ma H, Zhang J W, Deng M C, Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome p 450 enzymes. Planta Med. 2006; 72 126-131
205 Jin J, Shahi S, Kang H K, van Veen H W, Fan T-P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun. 2006; 345 1308-1314
206 Kitagawa S, Takahashi T, Nabekura T, Tachikawa E, Hasegawa H. Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells. Biol Pharm Bull. 2007; 30 1979-1981
207 Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, Zhang R, Wang H. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One. 2008; 3 e2697
208 Pokharel Y R, Kim N D, Han H K, Oh W K, Kang K W. Increased ubiquination of multidrug resistance 1 by ginsenoside Rd. Nutr Cancer. 2010; 62 252-259
209 Lee F C, Park J K, Ko J H, Lee J S, Kim K Y, Kim E K. Efects of Panax ginseng extract on the benzo(a)pyrene metabolizing enzyme system. Drug Chem Toxicol. 1987; 10 227-236
210 Lee Y J, Pantuck C B, Pantuck E J. Effect of ginseng on plasma levels of ethanol in the rat. Planta Med. 1993; 59 17-19
211 Gum S I, Jo S J, Ahn S H, Kim S G, Kim J T, Shin H M, Cho M K. The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J Ethnopharmacol. 2007; 112 568-576
212 Zhang R, Jie J, Zhou Y, Cao Z, Li W. Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. Am J Chin Med. 2009; 37 657-667
213 Zhu M, Chan K W, Ng L S, Chang Q, Chang S, Li R C. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol. 1999; 51 175-180
214 Yu C-T, Chen J, Teng X W, Tong V, Chang T K H. Lack of evidence for induction of CYP2B1, CYP3A23, and CYP1A2 gene expression by Panax ginseng and Panax quinquefolius extracts in adult rats and primary cultures of rat hepatocytes. Drug Metab Dispos. 2005; 33 19-22
215 Anderson G D, Rosito G, Mohustsy M A, Elmer G W. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003; 43 643-648
216 Jiang X, Williams K M, Liauw W S, Ammit A J, Roufogalis B D, Duke C C, Day R O, McLachlan A J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004; 57 592-599
217 Lee L S, Wise S D, Chan C, Parsons T L, Flexner C, Lietman P S. Possible differential induction of phase 2 enzyme and antioxidant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol. 2008; 48 599-609
218 Lee S-H, Ahn Y-M, Ahn S-Y, Doo H-K, Lee B-C. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med. 2008; 14 715-721
219 Andrade A S A, Hendrix C, Parsons T L, Caballero B, Yuan C-S, Flexner C W, Dobs A S, Brown T T. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med. 2008; 8 50
220 Lee F C, Ko J H, Park J K, Lee J S. Effects of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol. 1987; 14 543-546
221 Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med. 2004; 141 23-27
222 Jiang X, Blair E Y L, McLachlan A J. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol. 2006; 46 1370-1378
223 Janetzky K, Morreale A P. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm. 1997; 54 692-693
224 Rosado M F. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology. 2003; 99 111
225 Ames B N, Profet M, Gold L S. Dietary pesticides (99.99 % all natural). Proc Natl Acad Sci USA. 1990; 87 7777-7781
226 Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr Drug Metab. 2006; 7 67-81
227 Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab. 2000; 1 67-84
228 Hodgson E, Philpot R M. Interaction of methylenedioxyphenyl (1,3-benzodioxole) compounds with enzymes and their effects on mammals. Drug Metab Rev. 1974; 3 231-301
229 Adams N H, Levi P E, Hodgson E. Regulation of cytochrome P-450 isozymes by methylenedioxyphenyl compounds. Chem Biol Interact. 1993; 86 255-274
230 Nakajima M, Suzuki M, Yamaji R, Takashina H, Shimada N, Yamazaki H, Yoko T. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica. 1999; 29 1191-1202
231 Chatterjee P, Franklin M R. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003; 31 1391-1397
232 Gurley B J, Swain A, Hubbard M A, Hartsfield F, Thaden J, Williams D K, Gentry W B, Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008; 83 61-69
233 Sandhu R S, Prescilla R P, Simonelli T M, Edwards D J. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol. 2003; 43 1283-1288
234 Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporine A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005; 61 567-572
235 Xin H-W, Wu X-C, Li Q, Yu A-R, Zhong M-Y, Liu Y-Y. The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006; 28 25-29
236 Pan G Y, Wang G J, Liu X D, Fawcett J P, Xie Y Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002; 91 193-197
237 Tsai P L, Tsai T H. Hepatobiliary excretion of berberine. Drug Metab Dispos. 2004; 32 405-412
238 Shitan N, Tanaka M, Terai K, Ueda K, Yazaki K. Human MDR1 and MRP1 recognize berberine as their transport substrate. Biosci Biotechnol Biochem. 2007; 71 242-245
239 Nies A T, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008; 376 449-461
240 Qiu W, Jiang X H, Liu C X, Ju Y, Jin J X. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res. 2009; 23 1553-1558
241 Gurley B J, Swain A, Barone G W, Williams D K, Breen P, Yates C R, Stuart L B, Hubbard M A, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2007; 35 240-245
242 Gurley B J. University of Arkansas for Medical Sciences, Little Rock. Personal communication. October 9, 2011.
243 Gupta P K, Gurley B J, Barone G, Hendrickson H P. Clinical pharmacokinetics and metabolism of berberine and hydrastine following an oral dose of goldenseal supplement. Planta Med. 2010; 76 546
244 Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf. 2005; 4 779-794
245 Côté C S, Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun. 2004; 322 147-152
246 Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom. 2004; 18 2273-2281
247 Mathews J M, Etheridge A S, Black S R. Inhibition of human cytochrome P450 activities by kava extract and kava lactones. Drug Metab Dispos. 2002; 30 1153-1157
248 Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet L Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (kava-kava). Planta Med. 2002; 68 1055-1058
249 Zou L, Henderson G L, Harkey M R, Sakai Y, Li A. Effects of kava (kava-kava, ‘awa, yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine. 2004; 11 285-294
250 Mathews J M, Etheridge A S, Valentine J L, Black S R, Coleman D P, Patel P, So J, Burka L T. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos. 2005; 33 1555-1563
251 Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos. 2005; 33 1580-1583
252 Raucy J L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos. 2003; 31 533-539
253 Ma Y, Sachdeva K, Liu J, Ford M, Yang D, Khan I A, Chichester C O, Yan B. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos. 2004; 32 1317-1324
254 Yueh M-F, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos. 2005; 33 38-48
255 Lim S T S, Dragull K, Tang C-S, Bittenbender H C, Efird J T, Nerurkar P V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci. 2007; 97 214-221
256 Clayton N P, Yoshizawa K, Kissling G E, Burka L T, Chan P-C, Nyska A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp Toxicol Path. 2007; 58 223-236
257 Yamazaki Y, Hashida H, Arita A, Hamaguchi K, Shimura F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem Toxicol. 2008; 46 3732-3738
258 Guo L, Li Q, Xia Q, Dial S, Chan P-C, Fu P. Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem Toxicol. 2009; 47 433-442
259 Russman S, Barguil Y, Cabalion P, Rentsch K, Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens?. Clin Pharmacol Ther. 2005; 77 451-454
260 Srinivasan K. Black pepper and its pungent principle–piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. 2007; 47 735-748
261 Atal C K, Zutshi U, Rao P G. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol. 1981; 4 229-232
262 Friedman M, Levin C E, Lee S-U, Lee J-S, Ohnisi-Kameyama M, Kozukue N. Analysis by HPLC and LC/MS of pungent piperamides in commercial black, white, green, and red whole and ground peppercorns. J Agric Food Chem. 2008; 56 3028-3036
263 Dyer L A, Dodson C D, Richards J. Isolation, synthesis, and evolutionary ecology of Piper amides. In: Dyer L A, Palmer A N, editors Piper. A model genus for studies of evolution, chemical ecology, and trophic interactions. Boston: Kluwer Academic Publishers; 2004: 117-139
264 Siddiqui B S, Gulzar T, Begum S, Afshan F, Sattar F A. Insecticidal amides from fruits of Piper nigrum Linn. Nat Prod Res. 2005; 19 143-150
265 Park I-K, Lee S-G, Shin S-C, Park J-D, Ahn Y-J. Larvicidal activity of isobutylamides identified in Piper nigrum fruits against three mosquito species. J Agric Food Chem. 2002; 50 1866-1870
266 Atal C K, Dubey R K, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther. 1985; 232 258-262
267 Singh J, Dubey R K, Atal C K. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther. 1986; 236 488-493
268 Dalvi R R, Dalvi P S. Differences in the effects of piperine and piperonyl butoxide on hepatic drug-metabolizing enzyme system in rats. Drug Chem Toxicol. 1991; 14 219-229
269 Reen R K, Singh J. In vitro and in vivo inhibition of pulmonary cytochrome P450 activities by piperine, a major ingredient of Piper species. Indian J Exp Biol. 1991; 29 568-573
270 Reen R K, Jamwal D S, Taneja S C, Koul J L, Dubey R K, Wiebel F J, Singh J. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochem Pharmacol. 1993; 46 229-238
271 Reen R K, Roesch S F, Kiefer F, Wiebel F J, Singh J. Piperine impairs cytochrome P4501A1 activity by direct interaction with the enzyme and not by down regulation of CYP1A1 gene expression in the rat hepatoma 5 L cell line. Biochem Biophys Res Commun. 1996; 218 562-569
272 Reen R K, Wiebel F J, Singh J. Piperine inhibits aflatoxin B1-induced cytotoxicity and genotoxicity in V79 Chinese hamster cells genetically engineered to express rat cytochrome P4502B1. J Ethnopharmacol. 1997; 58 165-173
273 Koul S, Koul J L, Taneja S C, Dhar K L, Jamwal D S, Singh K, Reen R K, Singh J. Structure-activity relationship of piperine and its synthetic analogues for their inhibitory potentials of rat hepatic microsomal constitutive and inducible cytochrome P450 activities. Bioorg Med Chem. 2000; 8 251-268
274 Bhardwaj R K, Glaeser H, Becquemont L, Klotz U, Gupta S K, Fromm M F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002; 302 645-650
275 Subehan, Usia T, Kadota S, Tezuka Y. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Planta Med. 2006; 72 527-532
276 Suresh D, Srinivasan K. Influence of curcumin, capsaicin, and piperine on the rat liver drug-metabolizing enzyme system in vivo and in vitro. Can J Physiol Pharmacol. 2006; 84 1259-1265
277 Volak L P, Ghirmai S, Cashman J R, Court M H. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008; 36 1594-1605
278 Han Y, Tan T M C, Lim L-Y. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol Appl Pharmacol. 2008; 230 283-289
279 Hiwale A R, Dhuley J N, Naik S R. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian J Exp Biol. 2002; 40 277-281
280 Aher S, Biradar S, Gopu C L, Paradkar A. Novel pepper extract for enhanced P-glycoprotein inhibition. J Pharm Pharmacol. 2009; 61 1179-1186
281 Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull. 2010; 33 255-259
282 Najar I A, Sachin B S, Sharma S C, Satti N K, Suri K A, Johri R K. Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res. 2010; 24 454-458
283 Jin M J, Han H K. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. J Food Sci. 2010; 75 H93-H96
284 Selvendiran K, Thirunavukkarasu C, Singh J P V, Padmavathi R, Sakthisekaran D. Chemopreventative effect of piperine on mitochrondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Mol Cell Biochem. 2005; 271 101-106
285 Dalvi R R, Dalvi P S. Comparison of the effects of piperine administered intragastrically and intraperitoneally on the liver and liver mixed-function oxidases on rats. Drug Metabol Drug Interact. 1991; 9 23-30
286 Kang M H, Won S M, Park S S, Kim S G, Novak R F, Kim N D. Piperine effects on the expression of P4502E1, P4502B, and P4501A in rat. Xenobiotica. 1994; 24 1195-1204
287 Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine. 2002; 9 224-231
288 Zutshi R K, Singh R, Zutshi U, Johri R K, Atal C K. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. JAPI. 1985; 33 223-224
289 Bano G, Amla V, Raina R K, Zutshi U, Chopra C L. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med. 1987; 53 568-569
290 Bano G, Raina R K, Zutshi U, Bedi K L, Johri R K, Sharma S C. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol. 1991; 41 615-617
291 Velpandian T, Jasuja R, Bhardwaj R K, Jaiseal J, Gupta S K. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet. 2001; 26 241-248
292 Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res. 2006; 20 683-686
293 Kasibhatta R, Naidu M U R. Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomized, crossover, placebo-controlled study. Drugs R D. 2007; 8 383-391
294 Anand P, Kunnumakkara A B, Newman R A, Aggarwal B B. Bioavailability of curcumin: problems and promises. Mol Pharmacol. 2007; 4 807-818
295 Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol. 2009; 6 192-199
296 Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998; 64 353-356
297 Lambert J D, Hong J, Kim D H, Mishin V M, Yang C S. Piperine enhances the bioavailability of the tea polyphenol (−)-epigallocatechin-3-gallate in mice. J Nutr. 2004; 134 1948-1952
298 Panossian A, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol. 2008; 118 183-212
299 Schisandra monograph. Natural Medicines Comprehensive Database. Available at: http://naturaldatabase.therapeuticresearch.com Accessed October 26, 2010
300 Pan Q, Tao W, Lu Q, Hu X. Schisandrin B – a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun. 2005; 335 406-411
301 Pan Q, Lu Q, Zhang K, Hu X. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 2006; 58 99-106
302 Wan C-K, Zhu G-Y, Shen X-L, Chattopadhyay A, Dey S, Fong W-F. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol. 2006; 72 824-837
303 Yoo H H, Lee M, Lee M W, Lim S Y, Shin J, Kim D-H. Effects of Schisandra lignans on P-glycoprotein-mediated efflux in human intestinal Caco-2 cells. Planta Med. 2007; 73 444-450
304 Madgula V L M, Avula B, Choi Y W, Pullela S V, Khan I A, Walker L A, Khan S I. Transport of Schisandra chinensis extract and its biologically-active constituents across Caco-2 cell monolayers – an _in vit_ro model of intestinal transport. J Pharm Pharmacol. 2008; 60 363-370
305 Huang M, Jin J, Sun H, Liu G T. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol. 2008; 62 1015-1026
306 Slaninová I, Brezinová L, Koubiková L, Slanina J. Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells – study of structure-activity relationship. Toxicol In Vitro. 2009; 23 1047-1054
307 Iwata H, Tezuka Y, Usia T, Kadota S, Hiratsuka A, Watabe T. Inhibition of human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal medicines. J Tradit Med. 2004; 21 42-50
308 Iwata H, Tezuka Y, Kadota S, Hiratuska A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos. 2004; 32 1351-1358
309 Makino T, Mizuno F, Mizukami H. Does a Kampo medicine containing Schisandra fruit affect pharmacokinetics of nifedipine like grapefruit juice?. Biol Pharm Bull. 2006; 29 2065-2069
310 Mu Y, Zhang J, Zhang S, Zhou H-H, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther. 2006; 316 1369-1377
311 Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, Wang Y, Yu G, Kang A, Peng Y, Wang G, Chen X. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos. 2009; 37 2399-2407
312 Qin X L, Bi H C, Wang X D, Li J L, Wang Y, Xue X P, Chen X, Wang C X, Xu L J, Wang Y T, Huang M. Mechanistic understanding of the different effects of Wuzhi tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506). Int J Pharm. 2010; 389 114-121
313 Lee S B, Kim C Y, Lee H J, Yun J H, Nho C W. Induction of the phase II detoxification enzyme NQO1 in hepatocarcinoma cells by lignans from the fruit of Schisandra chinensis through nuclear accumulation of Nrf2. Planta Med. 2009; 75 1314-1318
314 Jin J, Bi H, Hu J, Zhong G, Zhao L, Huang Z, Huang M. Enhancement of oral bioavailability of paclitaxel after oral administration of schisandrol B in rats. Biopharm Drug Dispos. 2010; 31 264-268
315 Liu K-T, Cresteil T, Columelli S, Lesca P. Pharmacological properties of dibenzo[_a,c_]cyclooctene derivatives isolated from Fructus Schizandrae chinensis. II. Induction of phenobarbital-like hepatic monooxygenases. Chem Biol Interact. 1982; 39 315-319
316 Salbe A D, Bjeldanes L F. The effects of dietary Brussels sprouts and Schizandra chinensis on the xenobiotic-metabolizing enzymes of the rat small intestine. Food Chem Toxicol. 1985; 23 57-65
317 Xin H-W, Wu X-C, Li Q, Yu A-R, Zhu M, Shen Y, Su D, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol. 2007; 64 469-475
318 Jiang W, Wang X, Xu X, Kong L. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. Int J Clin Pharmacol Ther. 2010; 48 224-229
319 Xin H-W, Wu X-C, Li Q, Yu A-R, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin Pharmacol. 2009; 67 541-546
320 Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia. 1995; 64 3-42
321 Kroll D J, Shaw H S, Oberlies N H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007; 6 110-119
322 Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001; 61 2035-2063
323 Rambaldi A, Jacobs B P, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005; 100 2583-2591
324 Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007; 6 146-157
325 Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008; 15 9-20
326 El-Kamary S S, Shardell M D, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G, Strickland G T. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009; 16 391-400
327 Lorenz D, Lücker P W, Mennicke W H, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol. 1984; 6 655-661
328 Kim Y C, Kim E J, Lee E D, Kim J H, Jang S W, Kim Y G, Kwon J W, Kim W B, Lee M G. Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther. 2003; 41 593-596
329 Schrieber S J, Wen Z, Vourvahis M, Smith P C, Fried M W, Kashuba A D M, Hawke R L. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008; 36 1909-1916
330 Wen Z, Dumas T E, Schrieber S J, Hawke R L, Fried M W, Smith P C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008; 36 65-72
331 Hawke R L, Schrieber S J, Soule T A, Wen Z, Smith P C, Reddy R, Wahed A S, Belle S H, Afdhal N H, Navarro V J, Berman J, Liu Q-Y, Doo E, Fried M W. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010; 50 434-449
332 Miguez M-P, Anundi I, Sainz-Pardo L A, Lindros K O. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact. 1994; 91 51-63
333 Venkataramanan R, Ramachandran V, Komoroski B J, Zhang S, Schiff P L, Strom S C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos. 2000; 28 1270-1273
334 Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker R H, Beckurts T, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol. 2000; 86 250-256
335 Zuber R, Modrianský M, Dvorák Z, Rohovský P, Ulrichová J, Simánek V, Anzenbacher P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res. 2002; 16 632-638
336 Sridar C, Goosen T C, Kent U M, Williams J A, Hollenberg P F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyl-transferases. Drug Metab Dispos. 2004; 32 587-594
337 Patel J, Buddha B, Dey S, Pal D, Mitra A K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther. 2004; 11 262-277
338 Jancova P, Anzenbacherova E, Papouskova B, Lemr K, Luzna P, Veinlichova A, Anzenbacher P, Simanek V. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos. 2007; 35 2035-2039
339 Doehmer J, Tewes B, Klein K-U, Gritzko K, Muschick H, Mengs U. Assessment of drug-drug interaction for silymarin. Toxicol In Vitro. 2008; 22 610-617
340 Brantley S J, Oberlies N H, Kroll D J, Paine M F. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther. 2010; 332 1081-1087
341 Maitrejean M, Comte G, Barron D, El Kirat K, Conseil G, Di Pietro A. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett. 2000; 10 157-160
342 Zhang S, Morris M E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003; 304 1258-1267
343 Zhang S, Morris M E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res. 2003; 20 1184-1191
344 Chung S Y, Sung M K, Kim N H, Jang J O, Go E J, Lee H J. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res. 2005; 28 823-828
345 Morris M E, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 2006; 78 2116-2130
346 Miranda S R, Lee J K, Brouwer K L R, Wen Z, Smith P C, Hawke R L. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab Dispos. 2008; 36 2219-2226
347 Deng J W, Shon J-H, Shin H-J, Park S-J, Yeo C-W, Zhou H-H, Song P-S, Shin J-G. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res. 2008; 25 1807-1814
348 Javed S, Kohli K, Ali M. Patented bioavailability enhancement techniques of silymarin. Recent Pat Drug Deliv Formul. 2010; 4 145-152
349 Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on Idb 1016, a silybin-phosphatidylcholine complex, in normal human subjects. Eur J Drug Metab Pharmacokinet. 1990; 15 333-338
350 Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther. 1994; 32 614-617
351 Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos®). Altern Med Rev. 2005; 10 193-203
352 Kidd P M. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009; 14 226-246
353 Flaig T W, Gustafson D L, Su L-J, Zirrolli J A, Crighton F, Harrison G S, Pierson A S, Agarwal R, Glodé L M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007; 25 139-146
354 Flaig T W, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su L-J, Li Y, Harrison G, Agarwal R, Crawford E D, Lucia M S, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010; 70 848-855
355 Leber H W, Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung. 1976; 26 1603-1605
356 Piscitelli S C, Formentini E, Burstein A H, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002; 22 551-556
357 Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori V M, Gold W, Phillips E, Myers S, Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta analysis. Eur J Clin Pharmacol. 2005; 61 1-7
358 DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003; 23 866-870
359 van Erp N P H, Baker S D, Zhao M, Rudek M A, Guchelaar H-J, Nortier J W R, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res. 2005; 11 7800-7806
360 Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med. 2007; 73 1429-1435
361 Rao B N, Srinivas M, Kumar Y S, Rao Y M. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol Drug Interact. 2007; 22 175-185
362 Han Y, Guo D, Chen Y, Tan Z-R, Zhou H-H. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica. 2009; 39 694-699
363 Rajnarayana K, Reddy M S, Vidyasagar J, Krishna D R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung. 2004; 54 109-113
364 Han Y, Guo D, Chen Y, Chen Y, Tan Z-R, Zhou H-H. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol. 2009; 65 585-591
365 Ladas E J, Kroll D J, Oberlies N H, Cheng B, Ndao D H, Rheingold S R, Kelly K M. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010; 116 506-513
366 Hypericum Depression Trial Study Group . Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002; 14 1807-1814
367 Linde K, Berner M M, Kriston L. St. John's wort for major depression. Cochrane Database Syst Rev. 2008; (4) CD000448
368 Beerhues L. Hyperforin. Phytochemistry. 2006; 67 2201-2207
369 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St John's wort. J Nat Prod. 2010; 73 1015-1021
370 Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort interactions. Eur J Clin Pharmacol. 2006; 62 225-233
371 Whitten D L, Myers S P, Hawrelak J A, Wohlmuth H. The effect of St. John's wort extract on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol. 2006; 62 512-526
372 Zhou S-F, Lai X. An update on clinical drug interactions with the herbal antidepressant St John's wort. Curr Drug Metab. 2008; 9 394-409
373 Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John's wort drug interactions. Curr Drug Metab. 2008; 9 1027-1037
374 Borrelli F, Izzo A A. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009; 11 710-727
375 Moore L B, Goodwin B, Jones S A, Wisely W B, Serabjit-Singh C J, Willson T M, Collins J L, Kliewer S A. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA. 2000; 97 7500-7502
376 Wentworth J M, Agostini M, Love J, Schwabe J W, Chatterjee V K K. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol. 2000; 166 R11-R16
377 Watkins R E, Maglich J M, Moore L B, Wisely G B, Noble S M, Davis-Searlies P R, Lambert M H, Kliewer S A, Redinbo M R. 2.1 Å crystal structure of human PXR in complex with the St John's wort compound hyperforin. Biochemistry. 2003; 42 1430-1438
378 Caccia S. Antidepressant-like components of Hypericum perforatum extracts: an overview of their pharmacokinetics and metabolism. Curr Drug Metab. 2005; 6 531-543
379 Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a ‘modern herbal antidepressant, pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006; 45 449-468
380 Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M. Comparison of german St. John's wort products according to hyperforin and total hypericin content. J Am Pharm Assoc. 2001; 41 560-566
381 Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Nauyn Schmiedebergs Arch Pharmacol. 2007; 375 377-382
382 Mai I, Bauer S, Perloff E S, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther. 2004; 76 330-340
383 Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin H, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med. 2005; 71 331-337
384 Mueller S C, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski R G, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006; 62 29-36
385 Wang X D, Li J L, Su Q B, Guan S, Chen J, Du J, He Y W, Zeng J, Zhang J X, Chen X. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol. 2009; 67 255-261
386 Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008; 65 701-707
387 Ajazuddin S S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010; 81 680-689
388 Gurley B J. Emerging technologies for improving phytochemical bioavailability: benefits and risks. Clin Pharmacol Ther. 2011; 89 915-919
389 Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol. 2006; 46 1188-1194
390 Dürr D, Stieger B, Kullak-Ublick G A, Rentsch K M, Steinert H C, Meier P J, Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000; 68 598-604
391 Johne A, Schmider J, Brockmoller J, Stadelmann A M, Stormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol. 2002; 22 46-54
392 Mueller S C, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl E M, Sievers H, Frank B, Riethling A K, Drewelow B. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004; 75 546-557
393 Wang L S, Zhu B, El-Aty A M, Zhou G, Li Z, Wu J, Chen G L, Jie L, Tang Z R, Wang A. The influence of St. John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol. 2004; 44 577-581
394 Rengelshausen J, Banfield M, Riedel K, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli W, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005; 78 25-33
395 Dresser G K, Schwarz U I, Wilkinson G R, Kim R B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2005; 73 41-50
396 Wang Z, Hamman M A, Huang S M, Lesko L J, Hall S D. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002; 71 414-420
397 Xie R, Tan L H, Polasek E C, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens D J, Arakawa T, Knuth D W. CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol. 2005; 45 352-356
398 Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001; 70 518-524
399 Andren L, Andreasson Å, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007; 63 913-916
400 Wang Z, Gorski C, Hamman M A, Huang S-M, Lesko L J, Hall S D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001; 70 317-326
401 Markowitz J S, DeVane C L, Boulton D W, Carson S W, Nahas Z, Risch S C. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci. 2000; 66 133-139
402 Markowitz J S, Donovan J L, DeVane C L, Taylor R M, Ruan Y, Wang J S, Chavin K D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003; 290 1500-1504
403 Kawaguchi A, Ohmori M, Tsuruoka S-I, Nishiki K, Harada K, Miyamori I, Yano R-I, Nakamura T, Masada M, Fujimura A. Drug interaction between St John's wort and quazepam. Br J Clin Pharmacol. 2004; 58 403-410
404 de Maat M M, Hoetelmans R M, Math t R A, van Gorp E C, Meenhorst P L, Mulder J W, Beijnen J H. Drug interaction between St John's wort and nevirapine. AIDS. 2001; 15 420-421
405 Schwarz U, Hanso H, Dresser G, Kim R, Fromm M, Oertel R, Miehlke S, Kirch W. St. John's wort reduces oral bioavailability of talinolol in healthy volunteers. Clin Pharmacol Ther. 2002; 71 P33
406 Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther. 2004; 75 298-309
407 Mathijssen R H, Verweij J, de Bruijn P, Loos W J, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002; 94 1247-1249
408 Frye R F, Fitzgerald S M, Lagattuta T F, Hruska M W, Egorin M J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004; 76 323-329
409 Smith P. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy. 2004; 24 1508-1514
410 Hall S D, Wang Z, Huang S M, Hamman M A, Vasavada N, Adigun A Q, Hilligoss J K, Miller M, Gorski J C. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003; 74 525-535
411 Murphy P A, Kern S E, Stanczyk F Z, Westhoff C L. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005; 71 402-408
412 Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003; 56 683-690
413 Xu H, Williams K M, Liauw W S, Murray M, Day R O, McLachlan A J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol. 2008; 153 1579-1586
414 Barone G W, Gurley B J, Ketel B L, Lightfoot M L, Abul-Ezz S R. Drug interaction between St John's wort and cyclosporine. Ann Pharmacother. 2000; 34 1013-1016
415 Barone G W, Gurley B J, Ketel B L, Abul-Ezz S R. Herbal dietary supplements: a source for drug interactions in transplant recipients. Transplantation. 2001; 71 239-241
416 Bauer S, Starmer E, Johne A, Krager H, Budde K, Neumayer H-H, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol. 2003; 55 203-211
417 Bolley R, Zulke C, Kammerl M, Fischereder M, Kramer B K. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation. 2002; 73 1009
418 Hebert M F, Jeong M P, Yu-Luan C, Shahzad A, Anne M L. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2004; 44 89-94
419 Mai I, Budde K, Starmer E, Bauer S, Krager H, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant. 2003; 18 819-822
420 Eich-Hochli D, Oppliger R, Golay K P, Baumann P, Eap C B. Methadone maintenance treatment and St. John's wort – a case report. Pharmacopsychiatry. 2003; 36 35-37
421 Wang L S, Zhou G, Zhu B, Wu J, Wang J G, Abd El-Aty A M, Li T, Liu J, Yang T L, Wang D. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004; 75 191-197
422 Lundahl A, Hedeland M, Bondesson U, Knutson L, Lennernas H. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci. 2009; 36 433-443

Dr. Bill Gurley

Department of Pharmaceutical Sciences
UAMS, College of Pharmacy

4301 W. Markham St.

Little Rock, AR 72205

United States

Phone: +1 50 16 86 62 79

Fax: +1 50 15 26 65 10

Email: gurleybillyj@uams.edu